期刊
SEMINARS IN THROMBOSIS AND HEMOSTASIS
卷 34, 期 1, 页码 39-57出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-2008-1066023
关键词
thromboembolism; factor Xa inhibitor; factor IIa inhibitor; anticoagulants; clinical trial
Indirect systemic and direct oral factor Xa and direct oral factor IIa inhibitors with improved pharmacologic profiles compared with heparins and vitamin K antagonists are currently in clinical development. This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran). Specifically, the results of dose-finding studies for the prevention of venous thromboembolism after elective orthopedic surgery, the results of dose-finding studies for treatment of acute venous thromboembolism including prolonged prophylaxis of recurrent events, and the designs of ongoing clinical trials are reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据